Uncategorized
Inotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose Combination of Trabodenoson, a Novel Treatment for Glaucoma, and Latanoprost
LEXINGTON, Mass--(BUSINESS WIRE)--Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) today announced the initiation of a Phase 2 dose-ranging trial of a fixed-dose combination (FDC) of trabodenoson and latanoprost.
